Regulatory News: FDA’s real‑time clinical trials initiative: what changed, why it matters, and what to do now

On April 28, 2026, the U.S. Food and Drug Administration (FDA) announced major steps to advance real time clinical trials (RTCT) – including proof of concept trials that report selected endpoints and signals to the agency in real time, plus a Request for Information (RFI) for a broader pilot program planned to launch this summer.¹

What did FDA announce in April 2026?

FDA outlined two concrete actions:

• Proof of concept RTCTs: trials where FDA can review pre agreed signals and endpoints as data becomes available, rather than waiting for traditional reporting cycles.¹
• An RFI for a broader RTCT pilot (planned for this summer), with FDA accepting comments until May 29, 2026, and indicating it intends to publish final selection criteria in July and complete pilot selections in August. ¹

This is framed as an important step toward reducing gaps between phases (“continuous” trials), by giving regulators earlier visibility into key insights.

Why the FDA’s RTCT Initiative Matters for Sponsors?

RTCT signals a shift toward earlier, more continuous regulatory insight into trial data, raising the bar for data readiness, governance and decision-making well before formal submission milestones. The ultimate aim of this initiative is to reduce the drug development timeline, giving patients faster access to drugs.¹

In parallel, Europe is modernising clinical trial processes and transparency through EU-wide initiatives like ACT EU and CTIS, while expanding real world evidence capacity through DARWIN EU—all pointing to growing expectations for high quality, well-structured data across the lifecycle.^1-4

“Real-time clinical trials promise faster answers, but from a regulatory standpoint, the true challenge is ensuring those answers are stable enough to withstand FDA scrutiny as the data evolves in real time”

-    Alicia Baker McDowell, Vice President and Head of Global Regulatory Strategy

What actions should sponsors take now?

1. Re validate your development objectives and “decision points” 
   Map where earlier signal visibility could alter your program decisions (e.g., adaptive elements, safety monitoring triggers, endpoint hierarchy).
2. Pressure test data readiness and auditability
   Confirm you can support rapid signal review with strong traceability, role-based access, and clear definitions for what constitutes a “signal.”
3. Align regulatory engagement planning across regions
   Review how U.S. RTCT direction might interact with EU trial transparency, submission workflows, and evidence expectations—so your strategy stands up to both regulatory and commercial scrutiny.
4. Prepare data operations and governance 
   There will be a need to support faster signal review and traceability—otherwise teams risk rework later.

What RTCT guidance still doesn’t tell us

While RTCT guidance signals a major shift in how regulators engage with trial data, several critical uncertainties remain, as of May 2026

• Success criteria: What evidence or endpoints will validate RTCT vs. traditional models—and trigger wider rollout
• Data readiness standards: How data will be checked, cleaned, and contextualised before regulators see it in real time
• Regulatory decision-making: Whether preliminary or unverified signals could influence regulatory actions
• Data governance risks: Expectations around confidentiality, cybersecurity, and data-sharing boundaries
• Timelines to scale: When and how the pilot will transition into standard practice across development programmes, and whether it will be applied broadly or to select studies

How Fortrea supports the next step (CTA)

Fortrea integrates regulatory strategy, intelligence, and execution across the full asset lifecycle, helping our sponsors make confident decisions earlier and design development programs that stand up to regulatory and commercial scrutiny. Through continuous regulatory intelligence, regional fluency, and thoughtful use of advanced technology, we can reduce risk, prevent rework, and help keep development on track from early planning through post approval commitments.

Get in touch to discuss how RTCT could affect your clinical drug development, and how you can prepare your business with one of our regulatory team – contact us today

References

1. FDA Announces Major Steps to Implement Real Time Clinical Trials. https://www.fda.gov/news-events/press-announcements/fda-announces-major-steps-implement-real-time-clinical-trials (Last updated April 2026. Last accessed May 2026)
2. EMA: Accelerating Clinical Trials in the EU (ACT EU). https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/accelerating-clinical-trials-eu-act-eu (Last updated Jan 2025. Last accessed May 2026)
3. EMA: Clinical Trials Information System (CTIS). https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-information-system. (Last accessed May 2026)

4. EMA: Data Analysis and Real World Interrogation Network (DARWIN EU). https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu. (Last updated 2026. Last accessed May 2026)

    

FAQs

What are real time clinical trials (RTCT)?
RTCT is an approach where FDA reviewers can access selected endpoints and safety/efficacy signals as a trial progresses, based on criteria agreed in advance. The goal is earlier insight, with the potential to reduce delays between phases.¹

Does RTCT change informed consent, protocol review, or other governance requirements?
FDA’s announcement focuses on data access and review timing—not replacing core governance processes. Sponsors should still plan for standard oversight and documentation, while preparing for faster signal visibility and related operational demands.¹

How soon could the RTCT pilot affect development programs?
FDA is collecting input through an RFI with comments due May 29, 2026, and has indicated it plans to publish selection criteria in July and complete selections in August. That makes near term readiness planning valuable, even while broader implementation details continue to develop.¹

How does this connect to EU expectations (EMA)?
In the EU, clinical trials are increasingly supported through harmonised digital infrastructure and transparency requirements via CTIS and the broader ACT EU initiative. Separately, EMA’s DARWIN EU expands the use of real world evidence across the lifecycle. Together, these initiatives increase the importance of data quality, consistency, and readiness across regions.^2-4

Why choose Fortrea for regulatory strategy?
Fortrea supports integrated regulatory strategy and execution, including preparation for and facilitation of health authority interactions. Internal capability materials describe an annual volume of ~40–50 agency meetings globally, alongside support spanning pre submission planning through post approval commitments—helping reduce risk and re work through earlier, evidence-based decisions.